Back to News
Market Impact: 0.3
Takeda's ENTYVIO Treat-To-Target Trial Reduces UC Complication Risk By Nearly 70%; Stock Down
Source: Nasdaq
Healthcare & Biotech
Takeda reported Phase 4 VERDICT trial results indicating that ENTYVIO treatment aimed at achieving disease clearance significantly prolonged the time to first event in adults with moderate to severe ulcerative colitis. The supplied article text cuts off before identifying the event or providing numerical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
TAK0.70
More News
- Capital One, General Motors are among the stocks reporting this week with momentum. Here are the others
- Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly
- Merck KGaA to acquire Silence Therapeutics for $1.3 billion
- Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
- Silence Therapeutics jumps 59% on Merck takeover
- Goldman says play defense with these stocks if you're worried about the AI bull failing